The Chemours Company Announces Completion of Euro denominated Term Loan Repricing
The Chemours Company (NYSE: CC) has successfully completed the repricing of its Tranche B-3 Euro denominated Term Loan, which is due in August 2028. The Second Amendment reduces the applicable margin on the company's €415,000,000 Euro denominated term loan facility from adjusted EURIBOR + 4.00% to adjusted EURIBOR + 3.25%. The maturity date and other terms of the Term B-3 Euro Term Loan Facility remain substantially unchanged.
La Chemours Company (NYSE: CC) ha completato con successo la rivalutazione del suo prestito termico Tranche B-3 in euro, che scade ad agosto 2028. Il Secondo Emendamento riduce il margine applicabile alla linea di prestito termico denominato in euro di €415.000.000 da EURIBOR corretto + 4,00% a EURIBOR corretto + 3,25%. La data di scadenza e altre condizioni della linea di prestito termico B-3 in euro rimangono sostanzialmente invariate.
La Chemours Company (NYSE: CC) ha completado con éxito la reprogramación de su Préstamo a Plazo Tranche B-3 denominado en euros, que vence en agosto de 2028. La Segunda Enmienda reduce el margen aplicable a la línea de préstamo a plazo de €415,000,000 de Euroibor ajustado + 4,00% a Euroibor ajustado + 3,25%. La fecha de vencimiento y otros términos de la Línea de Préstamo a Plazo B-3 en euros permanecen sustancialmente sin cambios.
케모어스 컴퍼니(NYSE: CC)는 2028년 8월에 만기가 도래하는 유로화로 표시된 B-3 분할 대출의 재가격화를 성공적으로 완료했습니다. 제 2 수정안은 회사의 €415,000,000 유로화 대출 시설에 대한 적용 마진을 조정된 EURIBOR + 4.00%에서 조정된 EURIBOR + 3.25%로 낮춥니다. B-3 유로 대출 시설의 만기일 및 기타 조건은 본질적으로 변경되지 않습니다.
La Chemours Company (NYSE: CC) a réussi à compléter la revalorisation de son prêt à terme Tranche B-3 libellé en euros, qui doit arriver à échéance en août 2028. Le Deuxième Amendement réduit la marge applicable sur la facilité de prêt à terme de 415 000 000 € de l'EURIBOR ajusté + 4,00 % à l'EURIBOR ajusté + 3,25 %. La date d'échéance et d'autres conditions de la facilité de prêt à terme B-3 en euros demeurent essentiellement inchangées.
Die Chemours Company (NYSE: CC) hat erfolgreich die Neubewertung ihres Euro-denominierten Tranche B-3-Terminkredits abgeschlossen, der im August 2028 fällig wird. Die Zweite Änderung reduziert die anwendbare Marge für die €415.000.000 Euro-denominierte Kreditlinie von angepasstem EURIBOR + 4,00% auf angepassten EURIBOR + 3,25%. Das Fälligkeitsdatum und andere Bedingungen der Tranche B-3 Euro-Darlehensfazilität bleiben im Wesentlichen unverändert.
- Reduced borrowing costs with margin decrease of 75 basis points
- Improved debt terms while maintaining existing maturity schedule
- None.
Insights
The successful repricing of Chemours' Euro-denominated term loan represents a significant 75 basis point reduction in borrowing costs, from EURIBOR + 4.00% to EURIBOR + 3.25%. For a
The Second Amendment reduces the applicable margin in respect of the Company’s
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in
For more information, we invite you to visit chemours.com or follow us on X (formerly Twitter) @Chemours or LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours’ control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in Chemours’ filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241213987089/en/
INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300
investor@chemours.com
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com
Source: The Chemours Company
FAQ
What is the new interest rate margin for Chemours' (CC) Euro Term Loan after repricing?
What is the size of Chemours' (CC) Euro Term Loan facility?
When does Chemours' (CC) Euro Term Loan mature?